The Effects of Low Concentrations of Pravastatin on Placental Cells.
In vitro
Low concentration
Low-dose
Preeclampsia
Prevention
Statin
Journal
Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
received:
27
12
2023
accepted:
29
05
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
Pravastatin is a promising medication to treat preeclampsia. However, the appropriate dose of pravastatin for managing preeclampsia has not been established. In this in vitro study, we examined the effects of low concentrations of pravastatin (0.01 to 10 µM) under hypoxic conditions on two types of placental cells and found that pravastatin decreased sFlt-1 levels up to 34% in cytotrophoblast cells isolated from human term placentas. Furthermore, we showed that sFlt-1 levels in HTR-8/SVneo cells, a cell line derived from first trimester trophoblast cells, decreased after exposure to very low concentrations of pravastatin (0.01, 0.1 µM). We also examined the effects of pravastatin on uterine spiral artery remodeling-related events and showed in wound healing and tube formation assays that low concentrations of pravastatin upregulated cell migration and invasion in HTR-8/SVneo cells. These results demonstrated that a low dose of pravastatin has in vitro effects that suggest a potential for anti-preeclamptic effects in vivo.
Identifiants
pubmed: 38836966
doi: 10.1007/s43032-024-01611-x
pii: 10.1007/s43032-024-01611-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : JSPS KAKENHI Grant
ID : 20K09613
Organisme : JSPS KAKENHI Grant
ID : 17K11232
Informations de copyright
© 2024. The Author(s).
Références
Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia Lancet. 2021;398(10297):341–54.
pubmed: 34051884
National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]. London: National Institute for Health and Care Excellence (NICE); 2019.
ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132(1):e44–52.
Van Doorn R, Mukhtarova N, Flyke IP, et al. Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: a systematic review and meta-analysis. PLoS One. 2021;16(3):e0247782.
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–22.
doi: 10.1056/NEJMoa1704559
pubmed: 28657417
Staff AC. The two-stage placental model of preeclampsia: an update. J Reprod Immunol. 2019;134–135:1–10.
doi: 10.1016/j.jri.2019.07.004
pubmed: 31301487
Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58.
doi: 10.1172/JCI17189
pubmed: 12618519
pmcid: 151901
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
doi: 10.1146/annurev.pharmtox.45.120403.095748
pubmed: 15822172
pmcid: 2694580
Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121(1):143–50.
Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–63.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.
Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011;108(4):1451–5.
Ahmed A, Williams DJ, Cheed V, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2020;127(4):478–88.
doi: 10.1111/1471-0528.16013
pubmed: 31715077
Akbar MIA, Yosediputra A, Pratama RE, et al. INOVASIA study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1/PlGF levels. Am J Perinatol. 2024;41(3):300–9.
doi: 10.1055/a-1673-5603
pubmed: 34666379
Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):720.e1–7.
Costantine MM, West H, Wisner KL, et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. 2021;225(6):666.e1–5.
Döbert M, Varouxaki AN, Mu AC, et al. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation. 2021;144(9):670–9.
doi: 10.1161/CIRCULATIONAHA.121.053963
pubmed: 34162218
Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933–40.
doi: 10.1172/JCI86957
pubmed: 27454295
pmcid: 4966313
Motomura K, Okada N, Morita H, et al. A Rho-associated coiled-coil containing kinases (ROCK) inhibitor, Y-27632, enhances adhesion, viability and differentiation of human term placenta-derived trophoblasts in vitro. PLoS One. 2017;12(5):e0177994.
Chaudhary P, Babu GS, Sobti RC, Gupta SK. HGF regulate HTR-8/SVneo trophoblastic cells migration/invasion under hypoxic conditions through increased HIF-1α expression via MAPK and PI3K pathways. J Cell Commun Signal. 2019;13(4):503–21.
Deng CL, Ling ST, Liu XQ, Zhao YJ, Lv YF. Decreased expression of matrix metalloproteinase-1 in the maternal umbilical serum, trophoblasts and decidua leads to preeclampsia. Exp Ther Med. 2015;9(3):992–8.
doi: 10.3892/etm.2015.2194
pubmed: 25667666
pmcid: 4316985
Nugent WH, Mishra N, Strauss JF 3rd, Walsh SW. Matrix metalloproteinase 1 causes vasoconstriction and enhances vessel reactivity to angiotensin II via protease-activated receptor 1. Reprod Sci. 2016;23(4):542–8.
doi: 10.1177/1933719115607998
pubmed: 26438597
Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002;90(6):737–44.
doi: 10.1161/01.RES.0000014081.30867.F8
pubmed: 11934843
Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739–45.
doi: 10.1161/hc0602.103393
pubmed: 11839631
Depoix CL, Colson A, Mhallem-Gziri M, Hubinont C, Debieve F. Effects of chemotherapy on placental development and function using in vitro culture of human primary cytotrophoblasts. Invest New Drugs. 2020;38(3):547–57.
doi: 10.1007/s10637-019-00800-9
pubmed: 31155684
Vega M, Mauro M, Williams Z. Direct toxicity of insulin on the human placenta and protection by metformin. Fertil Steril. 2019;111(3):489–496.e5.
Liu M, et al. BCAM deficiency may contribute to preeclampsia by suppressing the PIK3R6/p-STAT3 signaling. Hypertension. 2022;79(12):2830–42.
doi: 10.1161/HYPERTENSIONAHA.122.20085
pubmed: 36252138
Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest. 1996;97(2):540–50.
doi: 10.1172/JCI118447
pubmed: 8567979
pmcid: 507049
Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214(3):356.e1–5.
Fujii T, Nagamatsu T, Morita K, et al. Enhanced HIF2α expression during human trophoblast differentiation into syncytiotrophoblast suppresses transcription of placental growth factor. Sci Rep. 2017;7(1):12455.
Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83.
doi: 10.1056/NEJMoa031884
pubmed: 14764923
Meyer N, Brodowski L, Richter K, von Kaisenberg CS, Schröder-Heurich B, von Versen-Höynck F. Pravastatin promotes endothelial colony-forming cell function, angiogenic signaling and protein expression in vitro. J Clin Med. 2021;10(2):183.
Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Kaitu’u-Lino TJ. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth. 2016;16:117.
Putra RA, Effendi JS, Permadi W, Bandiara R, Fauziah PN. Role of statin as inducer of Hmox-1 system in treatment of preeclampsia. Cell Mol Biol (Noisy-le-grand). 2018;64(10):1–4.
doi: 10.14715/cmb/2018.64.10.1
pubmed: 30084810
Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol. 2022;226(2S):S1171–81.
Wu D, Liu Y, Liu X, et al. Heme oxygenase-1 gene modified human placental mesenchymal stem cells promote placental angiogenesis and spiral artery remodeling by improving the balance of angiogenic factors in vitro. Placenta. 2020;99:70–7.
Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350:h1035.
Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014;36(6):506–9.
doi: 10.1016/S1701-2163(15)30565-X
pubmed: 24927189
Costantine MM, Clifton RG, Boekhoudt TM, et al. Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero. Am J Obstet Gynecol. 2023;229(2):153.e1–2.